Get the Stockscreener App
26.43
0.56%
-0.15
Pre-market:
26.06
-0.37
-1.40%
Genmab Adr stock is traded at $26.43, with a volume of 320.43K.
It is down -0.56% in the last 24 hours and down -1.93% over the past month.
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$26.58
Open:
$26.54
24h Volume:
320.43K
Relative Volume:
0.56
Market Cap:
$16.80B
Revenue:
$2.75B
Net Income/Loss:
$799.51M
P/E Ratio:
26.37
EPS:
1.0022
Net Cash Flow:
$940.04M
1W Performance:
-3.89%
1M Performance:
-1.93%
6M Performance:
-11.72%
1Y Performance:
-30.41%
1-Day Range:
$26.36
$26.59
1-Week Range:
$26.28
$27.18
52-Week Range:
$24.53
$37.97
Genmab Adr Stock (GMAB) Company Profile
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-23-24 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Dec-06-23 | Upgrade | UBS | Neutral → Buy |
| Nov-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-08-23 | Upgrade | DNB Markets | Sell → Buy |
| Oct-18-23 | Initiated | Exane BNP Paribas | Underperform |
| Sep-06-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-24-23 | Initiated | BTIG Research | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-31-23 | Initiated | UBS | Neutral |
| May-12-23 | Initiated | Morgan Stanley | Underweight |
| Dec-20-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-14-22 | Initiated | William Blair | Mkt Perform |
| Nov-11-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
| May-02-22 | Initiated | Cowen | Market Perform |
| Mar-16-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-01-21 | Initiated | Berenberg | Sell |
| Sep-16-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-24-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Jan-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-20 | Downgrade | Bryan Garnier | Neutral → Sell |
| Sep-08-20 | Initiated | SVB Leerink | Mkt Perform |
| Jun-25-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-23-20 | Initiated | Credit Suisse | Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Sep-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | Morgan Stanley | Overweight |
| Aug-12-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Genmab Adr Stock (GMAB) Latest News
Post-Trade Analysis: Genmab ADR (GMAB) Climbs 1.55, Closing at 26.90 - The Dwinnex
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial - GlobeNewswire Inc.
Market Recap: Genmab ADR (GMAB)’s Negative Momentum, Closing at 27.41 - The Dwinnex
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire Inc.
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewswire Inc.
Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewswire Inc.
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy - MSN
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet - Yahoo Finance
Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise? - Zacks Investment Research
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy - Yahoo Finance
GMAB vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
GMAB’s Stock Journey: What Investors Need to Know About Genmab ADR’s Performance - The InvestChronicle
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Zacks Investment Research
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Yahoo Finance Australia
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Nasdaq
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 - GlobeNewswire Inc.
ISS suggest Enhabit shareholders elect three AREX Capital nominees to board By Reuters - Investing.com
Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire Inc.
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock? - Zacks Investment Research
GMAB or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
GMAB vs. TECH: Which Stock Is the Better Value Option? - Yahoo Finance
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use - Zacks Investment Research
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now? - Yahoo Canada Shine On
Zacks.com featured highlights include Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner - Yahoo Lifestyle UK
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag - Yahoo Sport Australia
Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk - Yahoo New Zealand News
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo New Zealand News
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway - Benzinga
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Zacks Investment Research
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag - Yahoo New Zealand News
GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo New Zealand News
Genmab A/S executes share buyback program - Investing.com India
Genmab advances share buy-back program - Investing.com India
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now? - Yahoo Lifestyle Singapore
Ratio Revelations: Genmab ADR (GMAB)'s Financial Metrics in the Spotlight – DWinneX - The Dwinnex
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag - Yahoo Singapore News
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo Movies UK
Truist Securities ups Genmab shares target By Investing.com - Investing.com
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier - Yahoo Lifestyle UK
Genmab ADR (GMAB)'s stock chart: A technical perspective – US Post News - US Post News
Genmab ADR (GMAB) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Genmab completes $1.8 billion acquisition of ProfoundBio By Investing.com - Investing.com
What 9 Analyst Ratings Have To Say About Genmab - Benzinga
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now? - Yahoo Singapore News
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run? - Yahoo Singapore News
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year? - Yahoo Lifestyle UK
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year? - Yahoo Singapore News
500: Something went wrong - Investing.com
Genmab Announces Financial Results for the First Quarter of 2024 | GlobeNewswire by notified - NTB Kommunikasjon
Earnings call: Genmab reports strong Q1 growth, plans ProfoundBio acquisition - Investing.com
Decoding 9 Analyst Evaluations For Genmab - Benzinga
Genmab Adr Stock (GMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.06%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):